# Right Heart Failure â€“ Clinical Call Protocol

**Guidelines Referenced:**  
AHA/ACC/HFSA 2022 Guideline for the Management of Heart Failure, 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension, CHEST 2019 Guidelines for Management of High-Risk Pulmonary Embolism

## CARD INTERFACE LAYOUT

### Card 0 â€“ Dynamic Action Card (Node Dependent)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ RIGHT VENTRICULAR FAILURE                                   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“± CALLED BY: RN Johnson, CCU                               â”‚
â”‚ Patient: 58yo F with PAH, worsening SOB                     â”‚
â”‚                                                           â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                        â”‚
â”‚ â”‚     IMMEDIATE ASSESSMENT        â”‚                        â”‚
â”‚ â”‚ â˜‘ Elevate HOB 30-45 degrees     â”‚ [Position optimized]   â”‚
â”‚ â”‚ â˜‘ O2 to maintain SpO2 >92%      â”‚ [4L NC â†’ 94%]          â”‚
â”‚ â”‚ â˜‘ Echo ordered (RV function)    â”‚ [STAT portable]        â”‚
â”‚ â”‚ â˜‘ BNP, troponin, BMP, LFTs      â”‚ [Labs pending]         â”‚
â”‚ â”‚ â˜‘ CXR (evaluate RV size)        â”‚ [Completed]            â”‚
â”‚ â”‚ â˜ Consider PA catheter          â”‚ [If unstable]          â”‚
â”‚ â”‚ â˜ Pulmonary consult             â”‚ [PAH specialist]       â”‚
â”‚ â”‚                                â”‚                        â”‚
â”‚ â”‚ JVP: Prominent v waves          â”‚                        â”‚
â”‚ â”‚ Hepatomegaly: 4cm below RCM     â”‚                        â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                        â”‚
â”‚                                                           â”‚
â”‚ VITALS: BP 98/62, HR 105, RR 24, SpO2 94% on 4L           â”‚
â”‚                                                           â”‚
â”‚ RV FAILURE SIGNS:                                          â”‚
â”‚ â˜‘ Kussmaul's sign positive  â˜‘ Hepatojugular reflux +      â”‚
â”‚ â˜‘ TR murmur (3/6 holosystolic)  â˜‘ Ascites present         â”‚
â”‚                                                           â”‚
â”‚ âš ï¸ Avoid aggressive diuresis initially - RV preload dependentâ”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Example - RV Support Optimization Node:**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ RV FAILURE MANAGEMENT                                       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ HEMODYNAMICS: CVP 18, PAP 68/28 (mean 45), PCWP 12         â”‚
â”‚ Cardiac Output: 3.2 L/min (â†“)                               â”‚
â”‚                                                           â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                        â”‚
â”‚ â”‚     RV SUPPORT STRATEGY         â”‚                        â”‚
â”‚ â”‚                                â”‚                        â”‚
â”‚ â”‚ OPTIMIZE PRELOAD:               â”‚                        â”‚
â”‚ â”‚ Current CVP 18 (target 8-12)   â”‚ [Gentle diuresis]      â”‚
â”‚ â”‚ â˜‘ Furosemide 40mg IV q12h      â”‚ [Net -500-1000mL/d]    â”‚
â”‚ â”‚                                â”‚                        â”‚
â”‚ â”‚ REDUCE AFTERLOAD:               â”‚                        â”‚
â”‚ â”‚ â˜ Sildenafil 20mg PO TID       â”‚ [PDE-5 inhibitor]      â”‚
â”‚ â”‚ â˜ Inhaled NO/epoprostenol      â”‚ [If severe]            â”‚
â”‚ â”‚ â˜ Avoid hypoxia/acidosis       â”‚ [Optimize ventilation] â”‚
â”‚ â”‚                                â”‚                        â”‚
â”‚ â”‚ SUPPORT CONTRACTILITY:          â”‚                        â”‚
â”‚ â”‚ â˜ Milrinone 0.375 mcg/kg/min   â”‚ [Inodilator]          â”‚
â”‚ â”‚ â˜ Low-dose dobutamine          â”‚ [If hypotensive]       â”‚
â”‚ â”‚                                â”‚                        â”‚
â”‚ â”‚ MAINTAIN PERFUSION:             â”‚                        â”‚
â”‚ â”‚ MAP target: >65 mmHg           â”‚ [Current: 74]          â”‚
â”‚ â”‚ â˜ Norepinephrine if needed     â”‚ [Last resort]          â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                        â”‚
â”‚                                                           â”‚
â”‚ RHYTHM CRITICAL: Maintain sinus, control AF rate <80       â”‚
â”‚                                                           â”‚
â”‚ ğŸ“ Advanced HF Team: Consider RVAD evaluation if failing   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Card 1 â€“ Static Assessment/Etiologies

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ RIGHT HEART FAILURE ETIOLOGIES                             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ« PULMONARY CAUSES:                                        â”‚
â”‚ â€¢ PAH: Idiopathic, CTD-associated, HIV, portopulmonary     â”‚
â”‚ â€¢ Pulmonary venous HTN: Left heart failure (#1), MS/MR     â”‚
â”‚ â€¢ Lung disease: COPD (cor pulmonale), ILD, OSA            â”‚
â”‚ â€¢ Thromboembolic: Acute PE, chronic thromboembolic PH      â”‚
â”‚                                                           â”‚
â”‚ ğŸ’“ CARDIAC CAUSES:                                          â”‚
â”‚ â€¢ RV myocardial: RV infarction, ARVC, cardiomyopathy      â”‚
â”‚ â€¢ Valvular: Tricuspid regurgitation, pulmonic stenosis     â”‚
â”‚ â€¢ Congenital: ASD with shunt, Eisenmenger syndrome        â”‚
â”‚ â€¢ Pericardial: Constrictive pericarditis                  â”‚
â”‚                                                           â”‚
â”‚ PATHOPHYSIOLOGY - RV SPIRAL:                              â”‚
â”‚ â†‘ Afterload â†’ RV dilation â†’ TR develops â†’ â†‘ Preload â†’     â”‚
â”‚ Septal shift â†’ â†“ LV filling â†’ â†“ CO â†’ â†“ Coronary perfusion â†’â”‚
â”‚ RV ischemia â†’ Progressive failure                          â”‚
â”‚                                                           â”‚
â”‚ ASSESSMENT PRIORITIES:                                     â”‚
â”‚ Volume status (CVP, JVP), evidence of low CO, precipitatingâ”‚
â”‚ factors, home O2 use, prior echo/cath data, exercise capacityâ”‚
â”‚                                                           â”‚
â”‚ WHO FUNCTIONAL CLASS: I (asymptomatic) to IV (symptoms at rest)â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Card 2 â€“ Static Physical Exam/Medications

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ PHYSICAL EXAM & MEDICATIONS                                 â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ RV FAILURE SIGNS:                                          â”‚
â”‚ â€¢ Neck: Elevated JVP, prominent v waves (TR), Kussmaul's   â”‚
â”‚ â€¢ Cardiac: RV heave, loud P2, TR murmur, S3/S4 at LLSB    â”‚
â”‚ â€¢ Abdomen: Hepatomegaly, hepatojugular reflux, ascites     â”‚
â”‚ â€¢ Extremities: Pitting edema, cool, cyanotic              â”‚
â”‚                                                           â”‚
â”‚ ğŸ’Š DIURETIC STRATEGY (Start low, go slow):                 â”‚
â”‚ â€¢ Furosemide 20-40mg IV BID, monitor BP closely           â”‚
â”‚ â€¢ Add spironolactone 25mg, metolazone for resistance      â”‚
â”‚ â€¢ Goal: CVP 8-12 mmHg, net negative 500-1000mL/day        â”‚
â”‚                                                           â”‚
â”‚ ğŸ’Š PULMONARY VASODILATORS:                                 â”‚
â”‚ â€¢ PDE-5 inhibitors: Sildenafil 20mg TID, Tadalafil 40mg QD â”‚
â”‚ â€¢ Prostacyclins: Epoprostenol (IV), Treprostinil (SC/IV/inh)â”‚
â”‚ â€¢ ERA: Bosentan 125mg BID, Ambrisentan 5-10mg QD          â”‚
â”‚                                                           â”‚
â”‚ ğŸ’Š INOTROPIC SUPPORT:                                      â”‚
â”‚ â€¢ Milrinone 0.375-0.75 mcg/kg/min (inodilator effect)     â”‚
â”‚ â€¢ Dobutamine 2.5-5 mcg/kg/min (may worsen hypotension)    â”‚
â”‚                                                           â”‚
â”‚ ğŸ’Š SUPPORTIVE CARE:                                        â”‚
â”‚ â€¢ Oxygen: Target SpO2 >92%, consider nocturnal O2         â”‚
â”‚ â€¢ Anticoagulation: Warfarin INR 2-3 for PAH patients     â”‚
â”‚ â€¢ Iron replacement if deficient, Digoxin for AF rate controlâ”‚
â”‚                                                           â”‚
â”‚ âš ï¸ AVOID: Excessive preload reduction, systemic vasodilators,â”‚
â”‚ beta-blockers (unless AF), high PEEP ventilation, NSAIDs   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

## FLOWCHART (Bottom Panel â€“ Mermaid Algorithm)

```mermaid
graph TD
    A[RV Failure Recognition & Assess Severity]
    B{Hemodynamically Stable?}
    C[ICU Transfer & Invasive Monitoring]
    D[Identify Etiology Echo plus Labs]
    E[PA Catheter & Optimize Hemodynamics]
    F{Primary Etiology?}
    G[Pulm Vasodilators & Gentle Diuresis]
    H[Treat LHF & Optimize GDMT]
    I[Anticoagulation & Consider Lysis]
    J[Volume Support & Avoid Nitrates]
    K{Adequate CO?}
    L[Inotropic Support Milrinone/Dobutamine]
    M[Optimize Preload & Reduce Afterload]
    N{Response to Therapy?}
    O[Continue Current & Monitor Progress]
    P[Advanced Therapies Prostacyclins]
    Q{Improving?}
    R[Wean Support & Transition PO]
    S[MCS Evaluation RVAD/ECMO]
    T[Discharge Planning & Close Follow-up]
    U[Transplant Eval If Appropriate]

    A --> B
    B -- No --> C
    B -- Yes --> D
    C --> E
    D --> F
    F -- "Pulm HTN" --> G
    F -- "LV Failure" --> H
    F -- PE --> I
    F -- "RV Infarct" --> J
    E --> K
    K -- No --> L
    K -- Yes --> M
    G --> N
    N -- Good --> O
    N -- Poor --> P
    L --> Q
    Q -- Yes --> R
    Q -- No --> S
    O --> T
    R --> T
    P --> U
    S --> U
```

## INTERACTIVE ELEMENTS

### RV Function Calculator
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚      RV FUNCTION ASSESSMENT             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ TAPSE: [12] mm (normal >16)             â”‚
â”‚ RV S': [8] cm/s (normal >10)            â”‚
â”‚ FAC: [28]% (normal >35)                 â”‚
â”‚ RV/LV ratio: [1.2] (normal <0.9)        â”‚
â”‚                                         â”‚
â”‚ RV DYSFUNCTION: MODERATE                â”‚
â”‚                                         â”‚
â”‚ HEMODYNAMIC CALCULATIONS:               â”‚
â”‚ RAP: 18 mmHg | PAP: 68/28 (45)         â”‚
â”‚ PCWP: 12 mmHg | CO: 3.2 L/min          â”‚
â”‚                                         â”‚
â”‚ PVR = (45-12)/3.2 = 10.3 Wood units    â”‚
â”‚ (Normal <3, severe >5)                  â”‚
â”‚ TPG = 45-12 = 33 mmHg                   â”‚
â”‚ DPG = 28-12 = 16 mmHg                   â”‚
â”‚                                         â”‚
â”‚ INTERPRETATION: Pre-capillary PH        â”‚
â”‚                                         â”‚
â”‚ [CALCULATE PVR] [TREND DATA]            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### RV Failure Diuretic Protocol
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚    RV FAILURE DIURETIC PROTOCOL         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Current: CVP 18 mmHg (target 8-12)      â”‚
â”‚ Cr: 1.4 mg/dL | MAP: 73 mmHg            â”‚
â”‚                                         â”‚
â”‚ DIURETIC PLAN:                          â”‚
â”‚ â˜‘ Furosemide 40mg IV BID               â”‚
â”‚ â˜ Add spironolactone 25mg daily        â”‚
â”‚ â˜ Consider metolazone if resistant      â”‚
â”‚                                         â”‚
â”‚ RESPONSE MONITORING:                    â”‚
â”‚ UOP trend: 120â†’100â†’80 mL/hr             â”‚
â”‚ Net balance: -600 mL/24h                â”‚
â”‚ Weight: -1.2 kg | CVP: 18â†’15 mmHg       â”‚
â”‚                                         â”‚
â”‚ âš ï¸ CAUTION: BP dropping, rising Cr      â”‚
â”‚ Maintain adequate preload for RV        â”‚
â”‚                                         â”‚
â”‚ [ADJUST DOSE] [CHECK HEMODYNAMICS]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### PAH Treatment Ladder
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚    PULMONARY HTN TREATMENT LADDER       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ WHO Class: III | 6MWD: 280m | BNP: 450  â”‚
â”‚                                         â”‚
â”‚ CURRENT THERAPY:                        â”‚
â”‚ â˜‘ Supportive: O2, diuretics, warfarin   â”‚
â”‚ â˜‘ ERA Monotherapy: Ambrisentan 10mg QD  â”‚
â”‚                                         â”‚
â”‚ NEXT STEPS:                             â”‚
â”‚ â• Add PDE-5 Inhibitor                  â”‚
â”‚   â€¢ Sildenafil 20mg TID                 â”‚
â”‚   â€¢ OR Tadalafil 40mg daily             â”‚
â”‚                                         â”‚
â”‚ IF NO IMPROVEMENT (3-6 months):         â”‚
â”‚ â• Add Prostacyclin                     â”‚
â”‚   â€¢ Inhaled treprostinil QID            â”‚
â”‚   â€¢ OR IV epoprostenol                  â”‚
â”‚                                         â”‚
â”‚ [START COMBINATION] [CALCULATE RISK]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

## VIRTUA VOORHEES RIGHT HEART FAILURE ADDENDA

- **Pulmonary Hypertension Specialists:** Available via Transfer Center 856-886-5111 for complex PAH cases
- **Advanced Heart Failure Team:** RVAD evaluation and mechanical circulatory support consultation
- **Hemodynamic Monitoring:** Swan-Ganz catheter capabilities with ICU hemodynamic optimization
- **Quality Metrics:** Time to echocardiogram, appropriate diuretic dosing, specialist consultation rates

## REFERENCES

- AHA/ACC/HFSA. 2022 Guideline for the Management of Heart Failure
- ESC/ERS. 2022 Guidelines for Diagnosis and Treatment of Pulmonary Hypertension  
- CHEST. 2019 Guidelines for Management of High-Risk Pulmonary Embolism

**All steps follow current evidence-based guidelines for right heart failure with integrated pulmonary vasodilator therapy, gentle diuresis protocols, and optimization of hemodynamic support.**
